Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects - Topletz‐Erickson, Ariel R.; Lee, Anthony J.; Mayor, JoAl G.; Rustia, Evelyn L.; Abdulrasool, Layth I.; Wise, Amanda L.; Dailey, Ben; DeChenne, Sharon; Walker, Luke N.; Alley, Stephen C.; Endres, Christopher J. (Journal of clinical pharmacology, 2021)
Keywords: Adolescent; Adult; Aged; Animals; Antineoplastic Agents - pharmacology; Biological Transport - drug effects; Creatinine - blood; Cross-Over Studies; Dogs; Female; Glomerular Filtration Rate; Healthy Volunteers; HEK293 Cells; Humans; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Male; MATE; metformin; Metformin - pharmacokinetics; Middle Aged; OCT2; Organic Cation Transport Proteins - antagonists & inhibitors; Organic Cation Transporter 2 - antagonists & inhibitors; Oxazoles - pharmacology; pharmacokinetics; Pyridines - pharmacology; Quinazolines - pharmacology; Receptor, ErbB-2 - antagonists & inhibitors; renal function; tucatinib; Young Adult; pharmacokinetics; metformin; renal function; tucatinib; MATE; OCT2